Neutralizing antibodies play a dual role by limiting the effectiveness of viral vector-based gene therapies while also serving as promising therapeutic agents against viral infections.
Neutralizing antibodies (nAbs) are an important component of the immune system, which plays a dual role in modern medicine. On the one hand, they significantly limit the effectiveness of gene therapy based on viral vectors, reducing the effectiveness of treatment of diseases such as spinal muscular atrophy, which is especially evident with repeated administration of therapeutic vectors. On the other hand, nAbs is a promising tool for combating viral infections. This review systematizes current data on the mechanisms of nAbs formation against AAV vectors, analyzes the factors influencing their production, and discusses strategies to overcome this limitation, including modification of vectors and the development of methods to suppress the immune response. Special attention is paid to the prospects of using nAbs as therapeutic agents against viral infections. The key problems and possible directions of research development in this area are considered, which is important for improving approaches to the treatment of both rare genetic and infectious diseases.
Tsaregorodtseva et al. (Thu,) conducted a review in Viral vector based gene therapy and viral infections. Neutralizing antibodies was evaluated. Neutralizing antibodies play a dual role by limiting the effectiveness of viral vector-based gene therapies while also serving as promising therapeutic agents against viral infections.